Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,058.18 +37.34 (+3.66%)

Official Closing Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

Today 21:50 EST

Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.

Via The Motley Fool

3 Things Investors Need to Know About the Healthcare Sector in 2026 ↗

Today 9:33 EST

The most recent gold rush in weight loss drugs isn't done just yet.

Via The Motley Fool

Topics Economy

1 Brilliant Vanguard Index Fund to Buy Before It Soars 120%, According to a Wall Street Analyst ↗

Today 4:50 EST

Tom Lee says the S&P 500 (a benchmark for the U.S. stock market) can hit 15,000 by 2030.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

P/E Ratio Insights for Eli Lilly and Co ↗

February 05, 2026

Via Benzinga

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗

February 06, 2026

Via MarketBeat

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

February 06, 2026

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83...

Via MarketMinute

Topics Earnings Economy

AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months

February 06, 2026

In a breakthrough that many are calling the "Penicillin Moment" of the 21st century, researchers at the Massachusetts Institute of Technology, led by bioengineering pioneer James Collins, have...

Via TokenRing AI

Topics Artificial Intelligence

Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage

February 06, 2026

Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,...

Via MarketMinute

Topics Intellectual Property

Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore ↗

February 06, 2026

The market for obesity drugs may soon reach almost $100 billion.

Via The Motley Fool

The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market

February 06, 2026

The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

What Does the Market Think About Eli Lilly and Co? ↗

February 06, 2026

Via Benzinga

Why Shares of Novo Nordisk Stock Collapsed This Week ↗

February 06, 2026

The drugmaker is facing pricing pressures on its weight loss medications.

Via The Motley Fool

The Trillion-Dollar Divergence: Eli Lilly Hits Milestone While Novo Nordisk Faces 'Supply Chain Reset'

February 06, 2026

The global race for obesity market dominance reached a historic turning point this week as Eli Lilly and Company (NYSE: LLY) officially crossed the $1 trillion market capitalization threshold,...

Via MarketMinute

Topics Economy

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance

February 06, 2026

As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade...

Via Finterra

Topics Economy Government Intellectual Property

Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse

February 06, 2026

As of February 6, 2026, Biogen Inc. (NASDAQ: BIIB) stands at a critical crossroads in its nearly 50-year history. Once the undisputed titan of the Multiple Sclerosis (MS) market, the Cambridge-based...

Via Finterra

Topics Earnings Economy Intellectual Property

The $180 Billion Gamble: Alphabet’s High-Stakes AI Transformation in 2026

February 06, 2026

Date: February 6, 2026 Introduction Alphabet Inc. (NASDAQ: GOOGL / GOOG) currently stands at the most consequential crossroads in its 28-year history. Once the undisputed king of the information age,...

Via Finterra

Topics Artificial Intelligence Economy Initial Public Offering

These S&P500 stocks that are showing activity before the opening bell on Friday. ↗

February 06, 2026

Via Chartmill

Walmart Just Became the Newest Member of the Trillion-Dollar Club, and These 2 Non-AI Stocks May Be Next -- but There's a Catch ↗

February 06, 2026

Two standout companies from the same sector (no, not technology) have a clear path to follow in Walmart's footsteps.

Via The Motley Fool

Topics Artificial Intelligence Economy Government

Eli Lilly Stock Has Over 20% Upside, Analysts Say: Retail Seeks Pharma 'Safe Haven' As FDA Targets GLP-1 Copycats ↗

February 05, 2026

The stock’s rise followed FDA Commissioner Marty Makary's warning against companies marketing illegal copycat drugs.

Via Stocktwits

Topics Fraud Law Enforcement

Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. ↗

February 05, 2026

There's another fight brewing around GLP-1 drugs -- this time on the delivery side.

Via The Motley Fool

The Great Rebalancing: Why Investors are Fleeing Big Tech for the 'Safety' of Utilities and Healthcare

February 05, 2026

As of early February 2026, the long-standing dominance of high-growth technology and artificial intelligence (AI) stocks has hit a significant wall, triggering a massive "Great Rebalancing" across the...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most ↗

February 05, 2026

Via MarketBeat

Trade War 2.0: 25% Tariffs on Chips, Cars, and Medicine Reshape the Global Supply Chain

February 05, 2026

The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...

Via MarketMinute

Topics Earnings Economy

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY

February 05, 2026

From Scott+Scott Attorneys at Law LLP

Via Business Wire

Eli Lilly Just Delivered Fantastic News to Shareholders ↗

February 05, 2026

The stock price has climbed in the triple digits over three years.

Via The Motley Fool

Topics Government

Eli Lilly's 2026 Outlook Push Back Demand Fears: Analyst ↗

February 05, 2026

Cantor says Eli Lilly's 2026 outlook eases GLP-1 pricing worries, raises its price target, and expects strong sales growth driven by incretin drugs and orforglipron prescriptions.

Via Benzinga

Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗

February 05, 2026

The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes...

Via Stocktwits

Topics Economy Government World Trade

Thursday's session: top gainers and losers in the S&P500 index ↗

February 05, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.